Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment
CONCLUSION: PF tafluprost/timolol FC therapy provided statistically and clinically significant IOP reductions from Week 4 over the total 6-month period, in patients with OAG/OHT, regardless of the type of prior PGA or beta-blocker monotherapy used. Conjunctival hyperemia severity and CFS decreased significantly in prior bimatoprost and preserved latanoprost users, respectively.CLINICAL STUDY NUMBER: European Union electronic Register of Post-Authorization Studies (EU PAS) register number: EUPAS22204.PMID:35524840 | DOI:10.1007/s12325-022-02166-6
Source: Adv Data - Category: Epidemiology Authors: Francesco Oddone James Kirwan Fernando Lopez-Lopez Marina Zimina Claudia Fassari G ábor Holló VISIONARY Study Group Source Type: research
More News: Beta-Blockers | Epidemiology | Glaucoma | Hypertension | Latanoprost | Statistics | Study | Timolol | Travatan